Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Leukemia. 2021 Jul 9;35(10):2799–2812. doi: 10.1038/s41375-021-01338-7

Fig. 7. Co-targeting BCL2 and CXCR4 leads to enhanced efficacy against AML cells in vitro and in vivo.

Fig. 7

A Characteristics of relapsed AML patient samples utilized in (B). B Relative viability of primary AML cells treated with 10 μM Plerixafor (P), 50 nM Venetoclax (V) or a combination after 72 hr as measured by the MTT assay. (C) Survival curve of NSG mice (n = 5 per group) injected with AML PDX cells and Plerixafor, Venetoclax or a combination. Plerixafor (2.5 mg/kg s.c). and Venetoclax (50 mg/kg oral gavage) were administered five days a week for three weeks starting five days after AML cell injection. *p < 0.05, **p < 0.001, NS not significant.